cheap valuation and Dupixent-powered dividends
I view SNY as an attractive, buyable dividend growth stock given Dupixent's ~€15B sales and 25% y/y growth, a 5.4% starting yield with a 10-year dividend CAGR ~12%, a 64% payout ratio, and an 11.9x P/E that looks materially cheap versus peers despite the early-2030s Dupixent patent cliff.
Views SNY as attractively valued at 11.9x P/E with Dupixent generating roughly €15B in sales growing 25% annually, a 5.4% yield backed by a 12% ten-year dividend CAGR, despite the early-2030s patent cliff risk.
Publish-day $47.73 · 04/01Target $61.206mo
"This High-Yield Pharma Stock Looks Like a Bargain Right Now"